Taltz® — Venable's BiologicsHQ

U.S. License Holder:

Eli Lilly and Co.

Date of License:

March-22-2016

Last Update:

Nov-15-2024

FDA-Approved Indications

TALTZ (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of:

Patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy;

Adults with active psoriatic arthritis;

Adults with active ankylosing spondylitis;

Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

PGR2019-00043

U.S. Patent No.
10,011,654 (Antibodies Directed to IL-17A/IL-17F)

Patent Owner
Genentech, Inc.

Petitioner(s)
Eli Lilly & Co.

§ 102 Challenge
Y: Claims 1-7

Claim Types Challenged Under § 102
Composition of Matter Formulation

§ 102 Challenge Instituted
Y

§ 103 challenge
N

Final Written Decision Issued
Y

IPR Status
Challenges Also Include Written Description (Claims 1-7) and Enablement (Claims 1-7). Termination / Final Written Decision- Patent Owner Request for Adverse Judgment

U.S. Patent Litigations

PACER

Case No(s):

3:18-cv-01518 (S.D. Cal.)

U.S. Patent Nos.
10,011,654 (Antibodies Directed to IL-17A/IL-17F Heterodimers)

Plaintiffs
Genentech, Inc.

Defendants
Eli Lilly & Co.

Federal Circuit Appeal(s)
21-1874 (Denial of Attorney Fees)

Status
Voluntarily Dismissed; Federal Circuit Appeal of Denial of Attorney Fees Voluntarily Dismissed

BPCIA
N

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Taltz® (ixekizumab)

Taltz® (ixekizumab)

FDA-Approved Indications

Inter Partes Review Proceedings

IPR Case No(s):

PGR2019-00043

U.S. Patent Litigations

Case No(s):

3:18-cv-01518 (S.D. Cal.)

Related News

Filter Results

Or Search By:

Brand Name

Scientific Name

Company Name

Methodology

Disclaimer

Subscribe for Future Updates